[go: up one dir, main page]

ATE170753T1 - Androgenderivate zur hemming der aktivität der sexualsteroide - Google Patents

Androgenderivate zur hemming der aktivität der sexualsteroide

Info

Publication number
ATE170753T1
ATE170753T1 AT90909608T AT90909608T ATE170753T1 AT E170753 T1 ATE170753 T1 AT E170753T1 AT 90909608 T AT90909608 T AT 90909608T AT 90909608 T AT90909608 T AT 90909608T AT E170753 T1 ATE170753 T1 AT E170753T1
Authority
AT
Austria
Prior art keywords
inhibiting
activity
sex steroid
androgen
androgen derivatives
Prior art date
Application number
AT90909608T
Other languages
English (en)
Inventor
Fernand Labrie
Yves Merand
Original Assignee
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23486076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE170753(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Endorecherche Inc filed Critical Endorecherche Inc
Application granted granted Critical
Publication of ATE170753T1 publication Critical patent/ATE170753T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0048—Alkynyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0044—Alkenyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0055—Estrane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT90909608T 1989-07-07 1990-07-05 Androgenderivate zur hemming der aktivität der sexualsteroide ATE170753T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37669689A 1989-07-07 1989-07-07

Publications (1)

Publication Number Publication Date
ATE170753T1 true ATE170753T1 (de) 1998-09-15

Family

ID=23486076

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90909608T ATE170753T1 (de) 1989-07-07 1990-07-05 Androgenderivate zur hemming der aktivität der sexualsteroide

Country Status (17)

Country Link
US (1) US6110906A (de)
EP (1) EP0485392B1 (de)
JP (1) JP2959839B2 (de)
KR (1) KR0181264B1 (de)
AT (1) ATE170753T1 (de)
AU (3) AU5856090A (de)
CA (1) CA2063378A1 (de)
DE (1) DE69032648T2 (de)
ES (1) ES2121570T3 (de)
GR (1) GR1001164B (de)
HU (1) HUT60280A (de)
IE (1) IE902457A1 (de)
IL (1) IL94992A (de)
MY (1) MY106945A (de)
NZ (1) NZ234415A (de)
WO (1) WO1991000732A1 (de)
ZA (1) ZA905311B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
US5595985A (en) * 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
GR1001164B (el) * 1989-07-07 1993-05-24 Endorecherche Inc Παραγωγα αρρενογονου ορμονης προς χρησιν εις την αναστολην δραστηριοτητος της στεροειδους ορμονης φυλου
AU5851690A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Method of treatment of androgen-related diseases
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
AU680818B2 (en) * 1992-05-21 1997-08-14 Endorecherche Inc. Improved antiandrogens
HUT71514A (en) * 1992-05-21 1995-12-28 Endorecherche Inc Inhibitors of testosterone 5 alfa-reductase activity and pharmaceutical compositions containing the same
DE69329649D1 (de) * 1993-05-17 2000-12-14 Endorech Inc Verbesserte antiandrogene
DE69430356T2 (de) * 1993-11-19 2002-08-14 JENAPHARM GMBH & CO. KG Karzinostatisches Mittel für Hormontherapie, das Dienogest als wirksamer Bestandteil enthält
US6017924A (en) 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP0918774B9 (de) * 1996-06-27 2002-04-10 Ligand Pharmaceuticals Incorporated Androgen rezeptor modulator verbindungen und verfahren
US20050070516A1 (en) * 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US5879711A (en) * 1997-11-07 1999-03-09 Sequeira; Joel A. Stable antiandrogenic gel composition
EP1321146A3 (de) * 1998-03-11 2004-06-02 Endorecherche Inc. Typ 5 und Typ 3 17 Beta-Hydroxisteroid-Dehydrogenasehemmer und Verfahren zu ihrer Anwendung
BR9911115A (pt) * 1998-06-11 2001-12-04 Endorech Inc Composições farmacêuticas e usos para oandrost-5-eno-3 beta, 17 beta-diol
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
DE19860719A1 (de) * 1998-12-23 2000-06-29 Schering Ag Neue Testosteronderivate und ihre Verwendung zur Langzeittherapie von Androgen-abhängigen Erkrankungen
US6767903B1 (en) 1998-12-23 2004-07-27 Schering Ag New7α, 17α-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases
KR20020092902A (ko) * 1999-08-23 2002-12-12 쥬가이 세이야쿠 가부시키가이샤 항안드로겐제
EP1228083A2 (de) 1999-09-30 2002-08-07 Hollis-Eden Pharmaceuticals Inc. Therapeutische behandlung von durch androgenrezeptor hervorgerufene erkrankungen
WO2001062259A1 (en) 2000-02-25 2001-08-30 Hollis Eden Pharmaceuticals Method of treatment of prostate cancer
AU2001267904A1 (en) * 2000-06-30 2002-01-14 Chugai Seiyaku Kabushiki Kaisha Novel antiandrogenic agent
KR100348888B1 (en) * 2001-12-11 2002-08-14 Chang Eun Jung Method for relieving violence and spare diet of estrous deer and method for promoting growth of antlers thereof
US20060148725A1 (en) * 2001-12-21 2006-07-06 The Miriam Hospital Selective 11beta HSD inhibitors and methods of use thereof
WO2003059267A2 (en) * 2001-12-21 2003-07-24 Rhode Island Hospital SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
ITMI20030369A1 (it) * 2003-02-28 2004-09-01 Farmaka Srl Composizione cosmetica o farmaceutica ad uso topico per impedire o contrastare l'alopecia androgenetica.
WO2004089304A2 (en) * 2003-04-01 2004-10-21 Hollis-Eden Pharmaceuticals, Inc. Antiandrogens with marginal agonist activity and methods of use
WO2004097002A2 (en) * 2003-04-29 2004-11-11 The Miriam Hospital SELECTIVE TESTICULAR 11β-HSD INHIBITORS AND METHODS OF USE THEREOF
CA2582231A1 (en) * 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
DE202006021081U1 (de) * 2005-07-12 2012-05-08 Dmi Biosciences, Inc. Produkte zur Behandlung von Krankheiten
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
US8354396B2 (en) * 2006-11-17 2013-01-15 Harbor Therapeutics, Inc. Drug identification and treatment method
US20080221074A1 (en) * 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
US20080153792A1 (en) * 2006-11-17 2008-06-26 Frincke James M Drug Identification and Treatment Method
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US20100222315A1 (en) * 2008-09-24 2010-09-02 Harbor BioSciencs, Inc. Patient populations and treatment methods
US20100075937A1 (en) * 2008-09-24 2010-03-25 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
US20100227841A1 (en) * 2008-09-24 2010-09-09 Harbor BioSciencs, Inc. Patient populations and treatment methods
ES2523821T3 (es) 2009-06-22 2014-12-01 Ampio Pharmaceuticals, Inc. Procedimiento de tratamiento de enfermedades
WO2010151531A1 (en) * 2009-06-22 2010-12-29 Dmi Acquistion Corp. Methods and products for treatment of diseases
WO2011066582A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
CN103442737B (zh) 2011-01-20 2017-03-29 得克萨斯系统大学董事会 Mri标记、递送和提取系统及其制造方法和用途
SG10201705044YA (en) 2012-12-19 2017-07-28 Ampio Pharmaceuticals Inc Method for treatment of diseases

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3001988A (en) * 1960-07-19 1961-09-26 Searle & Co 3-oxygenated 17beta-aminoalkanamidoandrost-4/5-enes, 5alpha-androstanes corresponding, and intermediates thereto
US3300523A (en) * 1965-04-21 1967-01-24 Searle & Co 3-oxygenated 17beta-oxy-17alpha-pregnen-20-yn-21-yltri (alkyl/aryl) silanes and congeneric 3-desoxy-3, 5-dienes
GB1081494A (en) * 1965-09-14 1967-08-31 British Drug Houses Ltd 17ª‡-(alka-1',3'-diynyl)-steroids
US4161540A (en) * 1966-08-22 1979-07-17 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US3995060A (en) * 1972-06-20 1976-11-30 Schering Corporation Antiandrogenic agents and method for the treatment of androgen dependent disease states
US3875188A (en) * 1968-04-10 1975-04-01 Eugene E Galantay 17-Beta-alpha-lower alkyl allene-substituted steroids
FR2092780A2 (en) * 1970-06-18 1972-01-28 Roussel Uclaf 2-oxa-3-oxo-17-beta undecanoyloxy estra-4,9,11-triene - - long acting anabolic agent
FR2277082A1 (fr) * 1974-07-04 1976-01-30 Roussel Uclaf Nouveaux heptenes derives de la testosterone, leur procede de preparation et leur application a la fabrication d'antigenes
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US4329364A (en) * 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4039669A (en) * 1975-08-01 1977-08-02 Sterling Drug Inc. Composition for topical application and use thereof
IE44263B1 (en) * 1975-12-03 1981-09-23 Leo Pharm Prod Ltd New fusidic acid derivatives
DE2617646C2 (de) * 1976-04-22 1986-07-31 Hoechst Ag, 6230 Frankfurt Nonapeptid-amide und Decapeptid-amide mit Gonadoliberin-Wirkung, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
US4055641A (en) * 1976-05-10 1977-10-25 Richardson-Merrell Inc. Method of treating benign prostatic hypertrophy
GB1524747A (en) * 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4139638A (en) * 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
US4191759A (en) * 1978-04-13 1980-03-04 Merck & Co., Inc. N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
JPS5513273A (en) * 1978-07-13 1980-01-30 Kanebo Ltd Readily absorbable thiazolidine prodrug of anti- inflammatory corticosteroid and its drug composition
FR2430952A1 (fr) * 1978-07-13 1980-02-08 Roussel Uclaf Nouveaux derives acetyleniques de l'androst 4-ene, leur procede de preparation et leur application comme medicament
NZ207413A (en) * 1979-03-05 1984-11-09 Wisconsin Alumni Res Found Steroid intermediates in the preparation of 24,24-difluoro-25-hydroxy-vitamin d3
NZ197008A (en) * 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
FR2528434B1 (fr) * 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4481190A (en) * 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
DE3339295A1 (de) * 1982-11-15 1984-05-17 Schering AG, 1000 Berlin und 4709 Bergkamen 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung
AU565915B2 (en) * 1982-12-31 1987-10-01 Mortimer, C.H. Pharmaceutical composition of antibiotic and anti- androgen
GB8311678D0 (en) * 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
ES8502612A1 (es) * 1983-06-15 1985-02-01 Schering Ag Procedimiento para la preparacion de 13a-alquilgonanos
GB8327256D0 (en) * 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
IE58417B1 (en) * 1984-04-27 1993-09-22 Ici Plc Chemical derivatives
GB8410901D0 (en) * 1984-04-27 1984-06-06 Ici Plc Phenol derivatives
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
DE3478398D1 (en) * 1984-10-10 1989-07-06 Ile De France Synergistic contraceptive mixture
EP0188010A1 (de) * 1985-01-14 1986-07-23 Gist-Brocades N.V. Verfahren zur Herstellung von Steroiden, insbesondere von Zwischenprodukten in der Herstellung von Proligestonen und verwandte Verbindungen und erhaltene Zwischenprodukte
AU580843B2 (en) * 1985-02-07 1989-02-02 Schering Aktiengesellschaft 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
HU204063B (en) * 1986-10-10 1991-11-28 Gist Brocades Nv Process for producing 9-alpha-hydroxy steroids
HU203667B (en) * 1986-12-11 1991-09-30 Roussel Uclaf Process for producing synergetic zootechnical compositions containing three components
IE60780B1 (en) * 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
DE3702191A1 (de) * 1987-01-26 1988-11-03 Kloeckner Ferromatik Desma Rueckstroemsperre fuer die plastifizier- und spritzaggregate fuer spritzgiessmaschinen
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
EP0334425A1 (de) * 1988-03-24 1989-09-27 Akzo N.V. Delta-4-Androstenderivate
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
GR1001164B (el) * 1989-07-07 1993-05-24 Endorecherche Inc Παραγωγα αρρενογονου ορμονης προς χρησιν εις την αναστολην δραστηριοτητος της στεροειδους ορμονης φυλου

Also Published As

Publication number Publication date
DE69032648D1 (de) 1998-10-15
JP2959839B2 (ja) 1999-10-06
DE69032648T2 (de) 1999-04-08
GR1001164B (el) 1993-05-24
MY106945A (en) 1995-08-30
KR920703064A (ko) 1992-12-17
EP0485392A1 (de) 1992-05-20
ZA905311B (en) 1992-02-26
AU5856090A (en) 1991-02-06
WO1991000732A1 (en) 1991-01-24
JPH04506797A (ja) 1992-11-26
GR900100518A (en) 1991-12-10
AU692411B2 (en) 1998-06-04
US6110906A (en) 2000-08-29
HUT60280A (en) 1992-08-28
AU6748194A (en) 1994-09-08
ES2121570T3 (es) 1998-12-01
EP0485392B1 (de) 1998-09-09
NZ234415A (en) 1993-05-26
AU2559897A (en) 1997-09-04
IL94992A0 (en) 1991-06-10
KR0181264B1 (ko) 1999-03-20
IL94992A (en) 1998-01-04
HU9200049D0 (en) 1992-06-29
CA2063378A1 (en) 1991-01-08
IE902457A1 (en) 1991-02-13

Similar Documents

Publication Publication Date Title
ATE170753T1 (de) Androgenderivate zur hemming der aktivität der sexualsteroide
ATE161173T1 (de) Systeme mit gesteuerter freigabe und niedrigdosierte androgene
CA2050291A1 (en) Combination therapy for the treatment of estrogen sensitive diseases
DK0547151T3 (da) Behandlingsmåde til fremme af vægttab under anvendelse af et substitueret delta-5-androsten
SE7713341L (sv) Sett att framstella grenade och cykloalifatiska estrar ur androstan- och ostranserierna
ATE185812T1 (de) 17-spiromethylensteroide
RU94031127A (ru) Ингибиторы активности половых стероидов
CA2287387A1 (en) Methods and compositions for destruction of selected proteins
McEwen Binding and metabolism of sex steroids by the hypothalamic-pituitary unit: physiological implications.
KR950701527A (ko) 테스토스테론 5α 환원효소 활성 저해제(INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY)
Hauber et al. Adenosine A2a receptors in the nucleus accumbens modulate prepulse inhibition of the startle response
ATE451107T1 (de) 3-o-sulfamatsteroidderivate als hemmer von estronsulfatase
DE69126622D1 (de) 2beta,19-methylenamin überbrückte steroide als aromatasehemmer
Tweit et al. 15-Oxygenated Progesterones. A New Series of Synthetic Mineralocorticoid Antagonists
CA2000979A1 (fr) Ligands specifiques de recepteurs d'hormones steroides estrogenes et progestagenes, application et produits intermediaires de synthese
Shimizu et al. 17α-Methyl-17β-hydroxy-5α-androstano [2, 3-c] furazan (Androfurazanol), A New Active Anabolic Steroid
di Prisco et al. Effect of long-term isolation of the rat on in vitro biosynthesis of gonadal steroids from dehydroepiandrosterone
SE325270B (de)
PL359238A1 (en) 16, 17-carbocyclic condensed steroid compounds having selective estrogenic activity
NO159602C (no) Steroider som er nyttige for fremstilling av visse substituerte 17,17-ditto-androsten-forbindelser.
MA22913A1 (fr) Procede de synthese de peracylglycosides steroidiens .

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee